Coventon James
James Cook University, College of Medicine and Dentistry, 1 James Cook Drive, Douglas, Townsville, Queensland 4811, Australia.
J Bone Oncol. 2017 Aug 4;8:4-7. doi: 10.1016/j.jbo.2017.07.001. eCollection 2017 Sep.
To summarise the contemporary literature regarding sorafenib and its effectiveness as a novel treatment in advanced osteosarcoma.
Modern treatment has seen the cure rate of osteosarcoma increase to 65%. However, in patients who do not achieve remission, prognosis is poor, as there are no effective, consensual second line therapies. Sorafenib has emerged as a potentially viable drug to be used in this context.
A literature review was conducted evaluating articles pertaining to osteosarcoma and sorafenib.
Clinical studies were prioritised, but preclinical data was also evaluated to elaborate on mechanisms and potential targets for the future. Limitations of the review and data were explored.
In isolation, sorafenib was shown to only provide brief clinical benefit due to various described mechanisms. However, when combined with other drugs that addressed its weaknesses or other aspects of the pathogenesis of osteosarcoma, it proved to be effective in reducing disease progression in a variety of advanced cases. Further investigation into the use of sorafenib in combination therapy is needed. Specifically, the combination of sorafenib with denosumab has displayed potential to be an effective future treatment for osteosarcoma.
总结关于索拉非尼及其作为晚期骨肉瘤新型治疗方法有效性的当代文献。
现代治疗使骨肉瘤的治愈率提高到了65%。然而，对于未实现缓解的患者，预后较差，因为没有有效的、达成共识的二线治疗方法。索拉非尼已成为在这种情况下可能可行的药物。
进行了一项文献综述，评估与骨肉瘤和索拉非尼相关的文章。
优先考虑临床研究，但也评估了临床前数据，以详细阐述机制和未来的潜在靶点。探讨了综述和数据的局限性。
单独使用时，由于各种已描述的机制，索拉非尼仅显示出短暂的临床益处。然而，当与解决其弱点或骨肉瘤发病机制其他方面的其他药物联合使用时，它在多种晚期病例中被证明可有效减少疾病进展。需要进一步研究索拉非尼在联合治疗中的应用。具体而言，索拉非尼与地诺单抗联合使用已显示出成为骨肉瘤未来有效治疗方法的潜力。
